Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biogaia AB ADR

Healthcare US BIOGY

NoneUSD
0.00(0%)

Last update at 2026-05-14T21:27:50.567436Z

Day Range

--
LowHigh

52 Week Range

8.7911.46
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap990.38M
  • VolumeNone
  • P/E Ratio27.97
  • Dividend Yield-%
  • EBITDA468.92M
  • Revenue TTM1462.42M
  • Revenue Per Share TTM14.46
  • Gross Profit TTM 1063.29M
  • Diluted EPS TTM0.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 421.22M 447.82M 468.83M 447.61M 252.71M
Minority interest 0.00000M 0.00000M 0.00000M 0.00000M -
Net income 332.76M 351.39M 365.35M 373.77M 196.27M
Selling general administrative 47.65M 41.62M 39.25M 360.62M 234.98M
Selling and marketing expenses 513.23M 422.66M 363.26M - -
Gross profit 1128.58M 1030.74M 950.19M 801.93M 582.95M
Reconciled depreciation 24.67M 76.69M 24.86M 23.89M 27.24M
Ebit 429.67M 462.74M 440.91M 333.35M 246.72M
Ebitda 454.33M 539.44M 455.44M 476.89M 281.08M
Depreciation and amortization 24.67M 76.69M 14.53M - -
Non operating income net other - - - - -
Operating income 412.47M 423.37M 443.10M 334.67M 253.74M
Other operating expenses 1125.70M 999.35M 853.40M -0.53800M 0.00100M
Interest expense 8.45M 14.92M 0.81M 5.39M 1.13M
Tax provision 88.45M 96.43M 95.67M 73.84M 56.44M
Interest income 17.20M 39.37M 18.52M 7.96M 0.11M
Net interest income 8.75M 24.45M 15.82M 2.58M -1.02500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 88.45M 96.43M 103.48M 73.84M 56.44M
Total revenue 1538.17M 1422.72M 1296.51M 1103.96M 785.11M
Total operating expenses 716.11M 607.37M 507.09M 769.29M 531.37M
Cost of revenue 409.59M 391.98M 346.32M 302.03M 202.16M
Total other income expense net 8.75M 24.45M 25.73M - -
Discontinued operations - - - - -
Net income from continuing ops 332.76M 351.39M 437.42M 373.77M 196.27M
Net income applicable to common shares - - - 373.77M 196.27M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1597.81M 2034.01M 2333.19M 2213.97M 2128.05M
Intangible assets 0.70M 0.77M 46.23M 46.08M 48.09M
Earning assets - - - - -
Other current assets 417.76M 196.43M 43.16M 14.62M 0.20M
Total liab 283.59M 310.07M 302.85M 241.55M 250.69M
Total stockholder equity 1314.22M 1723.93M 2030.34M 1972.42M 1877.37M
Deferred long term liab - - - - -
Other current liab 199.14M 150.80M 96.06M 43.90M 28.24M
Common stock - 20.23M 20.20M 20.20M 20.20M
Capital stock 20.23M 20.23M 20.20M 20.20M 20.20M
Retained earnings 123.16M 491.04M 840.83M 772.73M 703.19M
Other liab - - - 71.64M 113.92M
Good will 146.50M 175.10M 165.17M 171.52M 149.23M
Other assets - - - 15.38M 2.80M
Cash 801.31M 1223.98M 1544.19M 1488.37M 1484.68M
Cash and equivalents - - - - -
Total current liabilities 199.14M 206.20M 195.74M 164.99M 126.95M
Current deferred revenue - - 8.53M - -
Net debt -801.31000M -1223.98400M -1544.19200M - -
Short term debt - 7.10M 0.27M - -
Short long term debt - - - - -
Short long term debt total - 29.48M 8.80M - -
Other stockholder equity 1314.22M 1174.15M 1169.31M 25.70M -0.02700M
Property plant equipment - - - 157.72M 153.63M
Total current assets 1219.07M 1610.18M 1874.43M 1797.48M 1752.08M
Long term investments - - - - -
Net tangible assets - - - 1754.82M 1680.05M
Short term investments - - - - -
Net receivables 216.17M 189.77M 105.88M 149.79M 164.46M
Long term debt - - - - -
Inventory 166.70M 152.89M 181.20M 142.84M 102.74M
Accounts payable 56.66M 48.30M 49.31M 32.05M 42.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 38.50M 15.94M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.05M 6.01M -0.00100M -
Deferred long term asset charges - - - - -
Non current assets total 378.73M 423.82M 458.76M 416.49M 375.98M
Capital lease obligations - - - - 10.40M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -14.07300M -36.73200M -18.14100M -22.22900M
Change to liabilities - - - -12.36900M -6.15100M
Total cashflows from investing activities -3.34300M -14.07300M -50.93500M -18.14100M -126.96700M
Net borrowings - - - -9.14300M -14.70100M
Total cash from financing activities -709.86700M -689.71800M -308.42100M -313.58800M -81.84600M
Change to operating activities - - - 54.26M 12.15M
Net income 412.47M 423.37M 443.10M 373.77M 196.27M
Change in cash -422.67400M -320.20800M 55.83M 3.69M 16.80M
Begin period cash flow 1223.98M 1544.19M 1488.37M 1484.68M 1467.88M
End period cash flow 801.31M 1223.98M 1544.19M 1488.37M 1484.68M
Total cash from operating activities 306.57M 373.22M 425.96M 318.94M 221.88M
Issuance of capital stock 0.00000M 20.82M -0.41700M -0.21400M 4.53M
Depreciation 24.67M 76.69M 25.28M 23.66M 20.78M
Other cashflows from investing activities 0.18M -0.31700M -0.14600M - -
Dividends paid 698.02M 696.78M 292.85M -73.56900M -68.87000M
Change to inventory -24.93400M 31.77M -40.88700M -34.12500M 9.82M
Change to account receivables - -85.64700M 3.75M -12.40300M -17.96500M
Sale purchase of stock - - -0.03928M -0.21400M -
Other cashflows from financing activities -11.84700M -4.40000M -4.40000M -3.11400M 1.73M
Change to netincome - - - -74.07900M 4.73M
Capital expenditures 3.60M 14.15M 48.71M 17.92M 6.38M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -42.92100M -49.71400M -1.10800M -4.64100M -2.14800M
Stock based compensation - - - - -
Other non cash items -87.64600M -77.13400M -41.31100M -9.10300M -2.35600M
Free cash flow 302.97M 359.06M 377.25M 301.03M 215.50M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIOGY
Biogaia AB ADR		 - -% - 27.97 - 6.81 7.97 6.88 23.31
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

Biogaia AB ADR

Kungsbroplan 3, Stockholm, Sweden, 112 27

Key Executives

Name Title Year Born
Mr. Peter Rothschild M.Sc. Econ., MBA Founder & Chairman 1950
Ms. Isabelle Valerie Ghislaine Ducellier CEO & Pres 1969
Mr. Alexander Kotsinas M.Sc. (Eng.). Exec. VP & CFO 1967
Jens Velling Chief Operating Officer NA
Mr. Gianfranco Grompone Chief Scientific Officer and VP of R&D 1975
Ms. Marika Isberg VP of Corp. Governance - Legal, Regulatory & Sustainability 1973
Eva Nelson Corp. Communications Mang. NA
Ms. Linda Hagglund VP of Marketing 1973
Ms. Angelika Kjelldorff VP of HR 1969
Sebastian Heimfors VP & Chief Commercial Officer 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.